Global Governments ‘Neglecting’ Vaccine Investment Post-COVID

Seth Berkley, epidemiologist and former CEO of Gavi, the vaccine alliance, has emphasized the importance of making “investments in peacetime” to prepare for pandemic threats and called for a “mindset change” among global governments.

Flagship Pioneering Event
Richard Hatchett, Seth Berkley, Rasmus Hansen and Labeeb Abboud speaking at the Flagship Pioneering event on 13 June • Source: Pink Sheet

“We have enough land-based missiles to blow up the world. And if they don’t work, or they fail, we have enough air-based missiles to blow up the world” says Seth Berkley, former CEO of Gavi, the international vaccine alliance.

His comments were intended to highlight the vast discrepancy between the investment made by governments to prepare for nuclear war...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United Kingdom

Responsible Antimicrobial Manufacturing A Must For UK’s Subscription Model Applicants

 

The UK will require all antibiotic manufacturers looking to apply for funding under its subscription payment model to demonstrate they are meeting waste discharge standards in a bid to reduce antimicrobial resistance.

Use AI In Health Technology Assessments Only When Valuable, England’s NICE Tells Pharma Firms

 

Pharmaceutical companies should only use AI in evidence generation and reporting where there is “demonstrable value from doing so,” according to England’s health technology assessment body, NICE.

Leqembi's UK Rollercoaster: A Yes From MHRA, A No From NICE

 

While the drug regulator has approved Eisai/Biogen’s early Alzheimer’s disease treatment, the health technology assessment institute is worried that its benefits are too small to justify its costs – a concern that Eisai has pledged to address.

Working With The Inspectors: UK’s eXmoor Gets License To Make ATMPs

 

It is “absolutely fundamental” that manufacturers of cell and gene therapies interact with inspectors from regulatory agencies to understand their expectations around good manufacturing practice, a compliance consultant at CDMO eXmoor pharma says.

More from Europe

EU Biosimilar Filings, Opinions And Approvals

 
• By 

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

UK Expedites Cost Negotiations For Companies Conducting ATMP & Early Phase Trials

 

Companies dealing with commercial costings or contracts with the National Health Service for early phase clinical trials or trials of advanced therapy medicinal products should soon be able to conclude their negotiations more quickly.

How To Decarbonize Pharma R&D

 

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.